Biagio Ricciuti, MD

Biagio Ricciuti, MD, spoke about future analyses and major takeaways of a study analyzing outcomes with frontline immunotherapy based on PD-L1 expression in patients with non–small cell lung cancer.

Biagio Ricciuti, MD, spoke about results of pembrolizumab monotherapy administration in patients with non–small cell lung cancer who had a PD-L1 tumor proportion score of 90% or more.

Biagio Ricciuti, MD, spoke about the 3-year follow-up and prolonged survival benefit in patients with non–small cell lung cancer who had very high PD-L1 expression of 90% or more.

Biagio Ricciuti, MD, spoke about combination immunotherapy regimens for patients with non–small cell lung cancer who did not respond well to prior treatment.

Biagio Ricciuti, MD, spoke about patients with non–small cell lung cancer with a very high PD-L1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy.